Mirae Asset Global Investments
ALXN

Mirae Asset Global Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Mirae Asset Global Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-91,204
Closed -$16.8M – 1810
2021
Q2 		$16.8M Buy
91,204
+19,207
+27% +$3.3M 0.05% 448
2021
Q1 		$11M Sell
71,997
-17,029
-19% -$2.63M 0.04% 505
2020
Q4 		$13.9M Buy
89,026
+6,278
+8% +$807K 0.05% 399
2020
Q3 		$9.47M Buy
82,748
+13,965
+20% +$1.51M 0.05% 401
2020
Q2 		$7.72M Buy
68,783
+2,539
+4% +$270K 0.05% 391
2020
Q1 		$5.95M Buy
66,244
+17,385
+36% +$1.71M 0.05% 397
2019
Q4 		$5.28M Buy
48,859
+6,934
+17% +$742K 0.03% 495
2019
Q3 		$4.11M Sell
41,925
-390,533
-90% -$44M 0.03% 513
2019
Q2 		$56.6M Buy
432,458
+32,374
+8% +$4.17M 0.39% 51
2019
Q1 		$54.1M Buy
400,084
+343,285
+604% +$42.7M 0.39% 52
2018
Q4 		$5.53M Buy
56,799
+1,917
+3% +$227K 0.05% 347
2018
Q3 		$7.62M Buy
54,882
+35,931
+190% +$4.51M 0.06% 327
2018
Q2 		$2.33M Sell
18,951
-7,380
-28% -$863K 0.03% 329
2018
Q1 		$2.93M Buy
26,331
+10,844
+70% +$1.3M 0.04% 289
2017
Q4 		$1.85M Sell
15,487
-47,836
-76% -$5.83M 0.02% 363
2017
Q3 		$8.87M Buy
63,323
+19,563
+45% +$2.66M 0.16% 112
2017
Q2 		$5.33M Buy
43,760
+14,407
+49% +$1.68M 0.09% 144
2017
Q1 		$3.56M Buy
29,353
+12,416
+73% +$1.6M 0.07% 193
2016
Q4 		$2.07M Buy
16,937
+2,363
+16% +$289K 0.05% 257
2016
Q3 		$1.79M Sell
14,574
-676
-4% -$87K 0.04% 257
2016
Q2 		$1.78M Sell
15,250
-1,926
-11% -$273K 0.05% 230
2016
Q1 		$2.39M Sell
17,176
-8,381
-33% -$1.23M 0.06% 192
2015
Q4 		$4.88M Buy
25,557
+1,859
+8% +$325K 0.16% 127
2015
Q3 		$3.71M Buy
23,698
+7,326
+45% +$1.34M 0.15% 135
2015
Q2 		$2.96M Buy
16,372
+10,285
+169% +$1.77M 0.09% 163
2015
Q1 		$1.05M Buy
6,087
+2,053
+51% +$372K 0.04% 292
2014
Q4 		$746K Buy
4,034
+520
+15% +$96.4K 0.03% 309
2014
Q3 		$583K Buy
+3,514
New +$577K 0.02% 340
2014
Q1 		– Sell
-9,720
Closed -$1.29M – 453
2013
Q4 		$1.29M Buy
9,720
+214
+2% +$25.7K 0.05% 237
2013
Q3 		$1.1M Sell
9,506
-2,995
-24% -$329K 0.05% 238
2013
Q2 		$1.15M Buy
+12,501
New +$1.2M 0.06% 215

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Mirae Asset Global Investments's ALXN Position: Q3 2021 in Review

Mirae Asset Global Investments sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 91,204 shares — an estimated $16.8M sold.

Mirae Asset Global Investments first reported a position in ALXN in Q2 2013 and held it in 31 quarters. The position peaked at $56.6M in Q2 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Mirae Asset Global Investments reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Mirae Asset Global Investments sold 91,204 Alexion Pharmaceuticals shares in Q3 2021, an estimated $16.8M.
  • Mirae Asset Global Investments first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Mirae Asset Global Investments's Alexion Pharmaceuticals position peaked at $56.6M in Q2 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Mirae Asset Global Investments's 13F filing for Q3 2021, filed 5 Nov 2021.